Epigenetics predicts the aggressiveness of Burkitt Lymphoma, a common pediatric tumor in developing countries
Researchers of the Cancer Epigenetics group at the Josep Carreras Leukaemia Research Institute have discovered that patients with Burkitt lymphoma — a common paediatric tumour in equatorial African countries and Latin America — can be classified into two main groups based on their epigenetic signature. The study, a high-level international collaboration co-led by Dr Manel Esteller, has demonstrated that one group, HypoBL, has a milder course of the disease, whereas the other, HyperBL, is associated with early relapses and shorter survival.
